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ABSTRACT: The cross-linked pentapeptides (2R,7R)-diami-
nooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) ((2R,7R)-
BVD-74D, (2R,7R)-1) and octanedioyl-bis(Tyr-Arg-Leu-Arg-
Tyr-amide) (2) as well as the pentapeptide Ac-Tyr-Arg-Leu-
Arg-Tyr-amide (3) were previously described as neuropeptide
Y Y4 receptor (Y4R) partial agonists. Here, we report on a
series of analogues of (2R,7R)-1 and 2 in which Arg2, Leu3, or
Arg4 were replaced by the respective aza-amino acids. The
replacement of Arg2 in 3 with a carbamoylated arginine building block and the extension of the N-terminus by an additional
arginine led to the high-aﬃnity hexapeptide Ac-Arg-Tyr-Nω-[(4-aminobutyl)aminocarbonyl]Arg-Leu-Arg-Tyr-amide (35), which
was used as a precursor for a D-amino acid scan. The target compounds were investigated for Y4R functional activity in assays
with complementary readouts: aequorin Ca2+ and β-arrestin 1 or β-arrestin 2 assays. In contrast to the parent compounds, which
are Y4R agonists, several ligands were able to suppress the eﬀect elicited by the endogenous ligand pancreatic polypeptide and
therefore represent a novel class of peptide Y4R antagonists.
1. INTRODUCTION
Among the neuropeptide Y (NPY) receptors, designated Y1R,
Y2R, Y4R, and Y5R,
1 the Y4R plays a special role because it
preferentially binds pancreatic polypeptide.2 Compared to the
Y1R, Y2R, and Y5R subtypes, fewer ligands by far (e.g., see
Figure 1) have been reported for the Y4R, in particular, high-
aﬃnity Y4R antagonists are still lacking.
3−6
Y4R agonists are considered to be potential antiobesity
agents.7,8 The diastereomeric mixture of the cross-linked
(“dimeric”) pentapeptide 1 (BVD-74D), a mimic of the C-
terminus of pancreatic polypeptide, was described as a high-
aﬃnity Y4R agonist,
4 having an eﬀect on food intake in mice.9
As reported previously, (2R,7R)-1 (note: in the following,
positions 2 and 7 refer to the stereo centers in the 2,7-
diaminosuberic acid moiety) was, by a factor of 3−10, more
potent than (2S,7S)-1, depending on the type of assay.10,11
Even though Y4R agonists should have higher clinical potential,
antagonists are of interest as well, in particular, as
pharmacological tools. The pentapeptide 3,6 a Y4R agonist
with an aﬃnity in the two-digit nanomolar range (Ki = 50 nM),
shares the same amino acid sequence with the peptide moieties
of 1. The incorporation of cyclic β-amino acids such as (1R,2S)-
2-aminocyclopentane-1-carboxylic acid resulted in partial
agonism.6
To investigate the impact of backbone modiﬁcations in Y4R
agonists on functional activity in more detail, additional
analogues of (2R,7R)-1, 2,11 and 3 were prepared. Here, we
report on the synthesis of Y4R ligands in which aza-amino acids
or D-amino acids were introduced. The title compounds were
characterized in binding and functional cellular assays with
complementary readouts.
2. RESULTS AND DISCUSSION
2.1. Chemistry. Aza-peptides contain at least one amino
acid in which the α-carbon atom is replaced by nitrogen.12 The
semicarbazide substructure reduces conformational ﬂexibil-
ity.13,14 Several studies have revealed that the incorporation
of aza-amino acids into bioactive peptides may result in a longer
duration of action or higher potencies compared to the parent
peptide.15−17 Aza-peptides can be prepared by the reaction of
an N-protected, N′-substituted hydrazine with an isocyanate.12
However, the synthesis of aza-peptides on a solid phase is
compromised by an intramolecular side-reaction of resin-bound
isocyanates that results in the formation of hydantoins (Figure
2A), lowering the yields of the target compounds and requiring
time-consuming puriﬁcation.18 To circumvent hydantoin
formation, N-Fmoc-aza1-dipeptides were prepared from N-
protected, N′-substituted hydrazines and benzyl ester-protected
amino acids, followed by hydrogenolytic debenzylation in
solution (Figure 2B).19
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Two diﬀerent Fmoc-protected hydrazines were synthesized
to mimic the side chains of Orn or Leu, respectively (Scheme
1). 3-Aminopropan-1-ol was Boc-protected and subsequently
oxidized under Parikh−Döring conditions using dimethyl
sulfoxide (DMSO) as an oxidant to form the aldehyde 7.
Condensation of (9H-ﬂuoren-9-yl)methyl hydrazinecarboxylate
8 and the aldehyde 7 or isobutyric aldehyde resulted in
hydrazones 9 and 11. Subsequent reduction using sodium
cyanotrihydridoborate gave access to the substituted hydrazines
10 and 12.
The benzyl ester-protected amino acids 14−16 were treated
with triphosgene to give the respective isocyanates in situ
(Scheme 2). Without puriﬁcation, the isocyanates were treated
with hydrazines 10 and 12 aﬀording the benzyl-protected N-
Fmoc-aza1-dipeptides in yields >70%. Subsequent ester
cleavage by hydrogenation gave access to the N-Fmoc-aza1-
dipeptides Fmoc-aza-Leu-Arg(Pbf)-OH (17), Fmoc-aza-Orn-
(Boc)-Tyr(tBu)-OH (18), and Fmoc-aza-Orn(Boc)-Leu-OH
(19). The dipeptides 17−19 were employed in solid phase
synthesis under the same conditions as those for the standard
Fmoc-protected amino acids, resulting in quantitative coupling
eﬃciencies.
To optimize the coupling of a resin-bound aza1-peptide, the
model peptide H-Ala-aza-Leu-Arg(Pbf)-NH2 (20) was synthe-
sized under various conditions (Scheme 3). When 3-[bis-
Figure 1. Amino acid sequence of human PP and structures of the described NPY Y4R agonists 1−3 and the Y1R/Y4R antagonist UR-MK188 (4).
Figure 2. Synthesis of aza-peptides on a solid phase (A) or in solution
(B).
Scheme 1. Synthesis of the Hydrazines 10 and 12a
aReagents and conditions: (a) Boc2O, Na2CO3, tetrahydrofuran (THF), 0 °C, 10 min, followed by room temperature (rt), 14 h; (b) sulfur trioxide
pyridine complex, DMSO, triethylamine (TEA), CH2Cl2, 0 °C, 1 h, followed by rt, 3 h; (c) Fmoc-Cl, MeCN/H2O (1:1), 0 °C, 10 min, followed by
rt, 12 h; (d) 7, CH2Cl2, 14 h; (e) isobutyraldehyde, CH2Cl2, 50 h; (f) sodium cyanotrihydridoborate, CH2Cl2/MeOH (4:3), 2 M HCl (pH 2−3), rt,
2−6 h.
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(dimethylamino)methyliumyl]-3H-benzotriazol-1-oxide hexa-
ﬂuorophosphate/hydroxybenzotriazole (HBTU/HOBt) was
used as coupling reagent at 35 °C, only 5−10% of the desired
products were formed. The same holds for the application of
the succinimidyl ester, Fmoc-Ala-OSu. The coupling eﬃciency
was increased to approximately 50% when the 7-aza-
benzotriazole derivative HATU was used as coupling reagent.
The best results (>50% coupling eﬃciency) were achieved by
in situ activation of Fmoc-Ala-OH to the corresponding acyl
chloride using triphosgene in THF. Surprisingly, when CH2Cl2
was used as a solvent instead of THF, only minor amounts of
20 were detected.
The dimeric aza-peptide (2R,7R)-26, an aza-Leu analogue of
(2R,7R)-1, was prepared from the protected pentapeptide 21
and the diacid (R,R)-24 (Scheme 4). For the preparation of the
aza-peptides 27−31, octanedioic acid disuccinimidyl ester (25)
was used for cross-linking. Cross-linking of 21 with 25 yielded
the dimeric aza-peptide 27, an aza-Leu analogue of 2.
Dimerization of the protected peptides 22 and 23 resulted in
the aza-peptides 28 and 30 containing ornithine instead of
arginine. Subsequently, guanidinylation was performed with
N,N′-di-Boc-1H-pyrazole-1-carboxamidine resulting in 29 and
31, which were aza-Arg-containing analogues of 2.
Very recently, we reported that the replacement of Arg2 with
the Nω-carbamoylated arginine 32 (Figure 3) in one of the
pentapeptide chains of 2 led to increased Y4R aﬃnity.
11
Similarly, 32 was used for the preparation of peptides 33−42
(Figure 4), which are analogues of the pentapeptide 3, on an
Fmoc-Sieber-PS resin by manual SPPS according to the Fmoc
strategy.
Finally, the applicability of 32 to the preparation of cyclic
peptides via head-to-side-chain cyclization was investigated.
Cyclic peptides are structurally more constrained than their
linear counterparts and can mimic secondary structural
elements of native peptides or proteins. Additionally, cyclic
peptides are less prone to enzymatic degradation. The
formation of head-to-tail cyclic peptides is often compromised
by rather rigid backbones. However, the side-chain of 32 is very
ﬂexible, facilitating an approximation of the activated C-
terminus and the terminal amino group. The hexapeptide 43
was prepared on an H-L-Tyr(tBu)-2CT resin followed by global
side-chain deprotection (Scheme 5). Cyclization was achieved
at a peptide concentration of 1 mM using benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexaﬂuorophosphate (PyBOP)
as coupling reagent. Under these conditions, the formation of
peptide dimers was not observed.
2.2. Competition Binding Studies at NPY Receptor
Subtypes. Y4R Binding. The Ki values of all of the target
Scheme 2. Synthesis of the N-Fmoc-aza1-dipeptides 17−19a
aReagents and conditions: (a) Benzyl alcohol, 4-dimethylaminopyridine (4-DMAP), dicyclohexylcarbodiimide (DCC), CH2Cl2, rt, 14 h, followed by
DEA/CH2Cl2 (1:8), rt; (b) triphosgene, N,N-diisopropylethylamine (DIPEA), CH2Cl2, rt, 90 min, followed by Pd/C, H2, MeOH, rt, 1 h.
Scheme 3. Incorporation of aza-Leu into the Model Peptide
20 via SPPSa
aReagents and conditions: (a) SPPS (Fmoc strategy), 17/HBTU/
HOBt/DIPEA (3/3/3/6 equiv), solvent DMF, 35 °C, 14 h; Fmoc
deprotection was carried out with 20% piperidine in DMF/N-methyl-
2-pyrrolidone (NMP) (8:2), rt, 2 × 10 min; (b) variation of the
conditions according to the table; Fmoc deprotection as under (a); (c)
Fmoc deprotection, followed by CH2Cl2/triﬂuoroacetic acid (TFA)
(97:3), 10 × 6 min.
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compounds were determined in competition binding studies on
live cells expressing Y4R (CHO-hY4R-Gqi5-mtAEQ cells) using
the radioligand [3H]UR-KK193 (45, Figure 5) (Table 1, Figure
6).11 The aﬃnities of the aza-peptides 27 (Ki = 134 nM), 29
(Ki = 52.7 nM), and 31 (Ki = 113 nM) were lower than the
aﬃnity of the respective reference compound 2 (Ki = 3.5 nM).
(R,R)-2,7-Diaminosuberic acid was superior to octanedioic acid
as a linker in the dimeric aza-peptides (cf. (2R,7R)-26: Ki =
30.8 nM), as in the case of peptide 1 compared to 2. The aza-
Orn precursors of 29 and 31, compounds 28 (Ki = 130 nM)
and 30 (Ki = 385 nM), bind to the Y4R as well, though with
lower aﬃnities compared to their aza-Arg counterparts.
Among the structural modiﬁcations of pentapeptide 3,
replacement of the N-terminal acetic acid with octanoic acid
(compound 33) resulted in an increase in Y4R aﬃnity by a
factor of almost six. The replacement of Arg2 in 3 with the
carbamoylated arginine 32 was even more favorable: the aﬃnity
of 34 (Ki = 19.5 nM) was 17-fold higher than the aﬃnity of its
parent compound 3. Extension of the N-terminus by an
additional arginine led to a further increase in aﬃnity: the Ki
value of compound 35 was in the single-digit nanomolar range
(Ki = 2.87 nM). Up to now, comparable binding data were
achieved only in the case of cross-linked or signiﬁcantly longer
linear peptides. The extension of the N-terminus of 3 by an
additional arginine alone had almost the same impact on Y4R
aﬃnity, that is, 36 (Ki = 3.43 nM) showed nearly the same
aﬃnity as peptide 35. Interestingly, the replacement of the
arginine adjacent to the C-terminus with the modiﬁed arginine
building block 32 was not tolerated (37: Ki = 501 nM).
Following the structural optimization of 3, a D-amino acid
scan was performed with the hexapeptide 35. Whereas
replacement of Arg1 or Tyr2 with D-Arg or D-Tyr, respectively,
was tolerated (cf. 41, 42), replacement of Leu4, Arg5, or Tyr6 by
the corresponding D-amino acid led to a marked decrease in
Y4R aﬃnity (cf. 38−40).
Previous studies revealed that C-terminal amidation is crucial
for Y4R binding of the endogenous ligand hPP.
21 Similarly, the
Scheme 4. Synthesis of “Homodimeric” Aza-Peptides 26−31a
aReagents and conditions: (a) SPPS (Fmoc strategy), Fmoc-aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv), solvent DMF/NMP (8:2), “double”
coupling at rt, 60 min or dipeptide (17, 18, or 19)/HBTU/HOBt/DIPEA (3/3/3/6), solvent: DMF, 35 °C, 14 h; Fmoc deprotection as under (a)
in Scheme 3; (b) triphosgene, DIPEA, THF, 35 °C, 14 h; Fmoc deprotection as under (a) in Scheme 3; (c) CH2Cl2/TFA (97:3), 10 × 6 min; (d)
HBTU, HOBt, DIPEA, anhydrous DMF, 35 °C, 16 h; (e) 1 equiv of 25 in 1% DIPEA in anhydrous DMF, followed by 2.5 equiv of 21, 22, or 23, 35
°C, 16 h; (f) TFA/H2O (95:5), rt, 2.5 h; (g) N,N’-di-Boc-1H-pyrazole-1-carboxamidine, DMF, DIPEA, rt, 4 h; Boc-deprotection, TFA/CH2Cl2/
H2O (10/10/1), rt, 3 h.
Figure 3. Structure of the Nω-carbamoylated arginine building block
32.20
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aﬃnity of the carboxylic acid 43 (IC50 > 5000 nM) was much
lower than the aﬃnity of the amide 35. Cyclization of 43
resulted in an increase in Y4R aﬃnity. However, the cyclic
peptide 44 (Ki = 1650 nM) was only a weak binder compared
to the linear analogue 35.
2.3. NPY Receptor Subtype Selectivity. Ki values of all of
the target compounds were also determined at the Y1, Y2, and
Y5 receptors using the radioligands [
3H]propionyl-pNPY (Y2R
and Y5R) or [
3H]UR-MK136 (46, Y1R, Figure 5). Neither the
linear peptides 34−43 nor the cyclic peptide 44 displayed
remarkable aﬃnity to the Y1, Y2, or Y5 receptors. Having a more
than 1000-fold selectivity for the Y4R over the other NPY
receptors, peptide 35 proved to be superior to (2R,7R)-1 and 2.
Only the pentapeptide 33 bound to the Y1R with a Ki value in
the submicromolar range (Ki (Y1R) = 589 nM), that is, the
lipophilic N-terminal octanoyl residue is disadvantageous with
respect to Y4R selectivity.
The cross-linked aza-peptides (2R,7R)-26, 27, and 29
displayed only low Y1R, Y2R, and Y5R aﬃnities, whereas the
aﬃnity of 31 (Ki = 53 nM) at the Y1R was markedly higher
than that of the peptide analogue 2. In a Fura-2 Ca2+ assay on
human erythroleukemia (HEL) cells, 31 revealed Y1R
antagonism (Figure 7) with a Kb value of 11.5 nM.
2.4. Functional Studies at the Y4R. The target
compounds were investigated for Y4R agonism and antagonism
in an aequorin Ca2+ assay as well as β-arrestin 1 and β-arrestin 2
recruitment assays on genetically engineered CHO or
HEK293T cells, respectively (for data see Table 2, Figures
8−10, SI Figures 1−8).
2.5. Y4R Agonism. (2R,7R)-1 was a partial agonist in both
the Ca2+ assay and the β-arrestin recruitment assays (α = 0.62,
(Ca2+ assay), α = 0.54 (β-arrestin 1) or 0.58 (β-arrestin 2),
Figure 8A,C,E). The pentapeptides 33 and 34, and the
hexapeptides 35 and 36, were partial agonists achieving
between 44 and 78% of the maximal response of hPP in both
the calcium and the arrestin assay (Figure 8). Y4R agonism was
retained, though at a lower level, when D-amino acids were
introduced into the N-terminal part of 35 (cf. 41, 42; Figure 8).
In contrast, the aza-peptides (2R,7R)-26, 27, and 31, the
carbamoyl-Arg modiﬁed peptides 37−40, including those
bearing D-amino acids in the C-terminus (38−40), as well as
the cyclic hexapeptide 44 were devoid of Y4R agonism in the
aequorin Ca2+ assay and the β-arrestin recruitment assays (SI
Figures 2−7). The aza-peptide 29 displayed weak partial
agonism with extremely low intrinsic activity (EC50 = 542 nM,
α = 0.07, (Ca2+ assay); EC50 = 875 nM, α = 0.09 (β-arrestin 1);
Figure 4. Primary structures of all investigated peptides.
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EC50 = 473, α = 0.12 (β-arrestin 2)). Compounds (2R,7R)-26
and 27 were also investigated for Y4R agonism in a luciferase
reporter gene assay. Surprisingly, both aza-peptides displayed
partial agonism in this assay (α = 0.81, EC50 = 176 nM
((2R,7R)-26), α = 0.75, EC50 = 220 nM (27)). Functional
assays with distal readouts such as the luciferase reporter gene
assay can reﬂect pronounced signal ampliﬁcations. It should be
taken into account that the incubation period in the luciferase
reporter gene assays was 4.5 h compared to 60 min for the
arrestin assays and a few seconds in the case of the aequorin
assay. Therefore, compounds displaying negligible agonistic
activity in assays with proximal readouts may show much higher
eﬃcacies in reporter gene assays, as demonstrated, for example,
for histamine H4 receptor ligands.
28 Likewise, (2R,7R)-1, a
partial agonist in the Ca2+ assay and the arrestin assay, appeared
as a full agonist in the luciferase assay.11
2.6. Y4R Antagonism. The incorporation of aza-amino
acids into the cross-linked peptides (2R,7R)-1 and 2 had an
impact on the quality of action. The dimeric aza-peptides
(2R,7R)-26, 27, 29, and 31 were able to suppress the response
elicited by the endogenous ligand hPP (Figure 9, SI Figure 8).
The introduction of D-amino acids into the C-terminal
tripeptide of 35 led to Y4R antagonism, with compound 40,
in which Leu4 was replaced by D-Leu, displaying the strongest
antagonism in the Ca2+ assay (Table 2, SI Figure 8).
Compound 37, in which Arg5 was replaced by the
carbamoylated arginine 32, and the cyclic hexapeptide 44
were identiﬁed as weak Y4R antagonists (Figure 10, SI Figure
1).
In summary, modiﬁcation of the C-terminal part of the
monomeric and cross-linked peptide partial agonists by the
introduction of aza-amino acids or D-amino acids as well as
rigidization of the backbone by head-to-side-chain cyclization
Scheme 5. Synthesis of the Head-to-Side-Chain Cyclic Peptide 43a
aReagents and conditions: (a) SPPS (Fmoc strategy), Fmoc-aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv), solvent DMF/NMP (8:2), double
coupling at rt, 60 min or 32/HBTU/HOBt/DIPEA (3/3/3/6), solvent: DMF, 35 °C, 14 h; Fmoc deprotection as under (a) in Scheme 3; (b)
CH2Cl2/TFA (97:3), 10 × 6 min; (c) TFA/H2O (95:5), rt, 2.5 h; (d) PyBOP, HOBt, DIPEA, DMF, rt, 24 h.
Figure 5. Structures of the Y4R radioligand [
3H]UR-KK193 (45) and the Y1R radioligand [
3H]UR-MK136 (46).
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changed the quality of action to antagonism in the aequorin
and β-arrestin assays. Unfortunately, these modiﬁcations went
along with a decrease in Y4R aﬃnity. The EC50 values of the
reported Y4R partial agonists (33−36, 41, 42) were
substantially higher than the Ki values. This eﬀect was
previously discussed and can be attributed to the presence or
absence of sodium ions in the buﬀers.11,29
3. CONCLUSIONS
The aﬃnity and potency of the Y4R partial agonist 3 was
considerably increased by the replacement of Arg2 with the
carbamoylated arginine 32 and the introduction of an
additional arginine at the N-terminus. Several backbone
modiﬁcations of the C-terminal tripeptide (e.g., the introduc-
tion of aza-amino acids or D-amino acids) of 35 as well as head-
to-side-chain cyclization changed the quality of action of the
linear or dimeric Y4R peptide ligands from partial agonism to
antagonism. The resulting compounds displayed weaker Y4R
antagonism than the reported Y4R antagonist 4. However, due
to their extremely facile synthetic accessibility, linear peptides
derived from 35 containing D-amino acids (e.g., 40 (Ki = 248
nM)) are promising building blocks for further structural
modiﬁcations and might pave the way for the development of
peptide Y4R antagonists with increased aﬃnity.
4. EXPERIMENTAL SECTION
4.1. Chemistry: General Conditions. Chemicals and
solvents were purchased from commercial suppliers and used
without further puriﬁcation unless otherwise indicated. DMF
for peptide synthesis, NMP for peptide synthesis, 4-DMAP,
sodium cyanotrihydroborate, and HOBt hydrate were from
Acros Organics/Fisher Scientiﬁc (Nidderau, Germany). Fmoc-
Sieber-PS resin (0.61 mmol/g), Fmoc-Arg(Pbf)-OH, Fmoc-
Tyr(tBu)-OH, H-L-Tyr(tBu)-2CT resin (0.68 mmol/g),
PyBOP, and HBTU were from Iris Biotech (Marktredwitz,
Germany). MeCN for HPLC (gradient grade), Fmoc-Leu-OH,
DCC, sulfur trioxide pyridine complex, hydrazine hydroxide,
and methanol were from Merck (Darmstadt, Germany).
Triﬂuoroacetic acid, TEA, triphosgene, Fmoc chloride,
isobutyraldehyde, DEA, CH2Cl2, diethyl ether, and Triton X-
100 were from Sigma-Aldrich (Deisenhofen, Germany); di-tert-
butyl dicarbonate (>97%) and 3-aminopropan-1-ol were from
Alfa Aesar (Karlsruhe, Germany). DIPEA (99%) was from
ABCR (Karlsruhe, Germany), and Fmoc-Ala-OSu was from
Advanced Chemtech (Louisville, KY). Bovine serum albumin
(BSA) and bacitracin were from Serva (Heidelberg, Germany)
and coelenterazin h was obtained from Biotrend (Cologne,
Germany). Human pancreatic polypeptide and porcine NPY
were from Synpeptide (Shanghai, China). The synthesis of
(2R,7R)-1,11 3,6 4,5 24,11 25,30 32,20 45,11 46,22 and
[3H]propionyl-pNPY24 was previously described. Millipore
water was used throughout for the preparation of buﬀers and
HPLC eluents. Stock solutions of test compounds were
prepared in Millipore water containing 0.1% TFA. Poly-
propylene reaction vessels (1.5 or 2 mL) with a screw cap (Süd-
Laborbedarf, Gauting, Germany) were used for small scale
reactions (e.g., the preparation of 44) and for the storage of
stock solutions. Thin-layer and column chromatography, NMR
spectroscopy, mass spectrometry, preparative and analytical
Table 1. Binding Data at NPY Receptor Subtypes
Y1R Y2R Y4R Y5R
compd Ki [nM]
a Ki [nM]
b Ki [nM]
c Ki [nM]
d
hPP 440e >5000e 0.65f 17e
(2R,7R)-1 440f 830f 0.45f 1500f
2 720f 1700f 3.5f 280f
3 >5000 >5000 337 ± 110 >5000
4 24g 920g 660f >5000g
(2R,7R)-26 1840 ± 380 >5000 30.8 ± 7.5 >5000
27 574 ± 49 >5000 134 ± 20 2700 ± 490
28 n.d. n.d. 130 ± 39 n.d.
29 3730 ± 350 >5000 52.7 ± 7.1 3560 ± 440
30 n.d. n.d. 385 ± 127 n.d.
31 53 ± 12 3270 ± 870 113 ± 14 2100 ± 240
33 589 ± 120 >5000 56.9 ± 5.3 3440 ± 210
34 >5000 >5000 19.5 ± 2.6 >5000
35 4830 ± 1400 >5000 2.87 ± 0.78 >5000
36 1180 ± 380 >5000 3.43 ± 1.3 >5000
37 1120 ± 270 >5000 501 ± 200 >5000
38 >5000 >5000 724 ± 140 >5000
39 >5000 >5000 568 ± 76 >5000
40 >5000 >5000 248 ± 23 >5000
41 >5000 >5000 10.4 ± 3.3 >5000
42 >5000 >5000 40.5± 15 >5000
43 >5000 >5000 >5000 >5000
44 >5000 >5000 1650 ± 290 >5000
aRadioligand competition binding assay with 4622 (Kd = 6.2 nM, c = 4 nM) using MCF-7-hY1 cells.
23 bRadioligand competition binding assay with
[3H]propionyl-pNPY24 (Kd = 1.4 nM, c = 1 nM) using CHO-hY2-Gqi5-mtAEQ cells.
25 cRadioligand competition binding assay with 4511 (Kd = 0.67
nM, c = 0.6 nM) using CHO-hY4R-Gqi5-mtAEQ cells.
26 dRadioligand competition binding assay with [3H]propionyl-pNPY (Kd = 4.83 nM, c = 4
nM) using HEC-1b hY5R cells.
27 eKi value reported by Berlicki et al.
6 fKi value reported by Kuhn et al.
11 gKi value reported by Keller et al.
5 Presented
are mean values ± SEM from at least three independent experiments (performed in triplicate). n.d.: not determined.
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HPLC, as well as freeze-drying were performed as described
previously.11
4.2. Compound Characterization. Compounds were
characterized as described previously.11 Purities determined
by reversed-phase high-performance liquid chromatography
(RP-HPLC) were >95%.
4.3. Chemistry: Experimental Protocols and Analytical
Data. General Procedure for Solid Phase Peptide
Synthesis. Peptides were synthesized by manual SPPS using
the Fmoc strategy on an Fmoc-Sieber-PS resin or an H-L-
Tyr(tBu)-2CT resin (43) as described with minor modiﬁca-
tions. Five milliliters Discardit II syringes (Becton Dickinson,
Heidelberg, Germany) were equipped with 35 μm polyethylene
frits (Roland Vetter Laborbedarf, Ammerbuch, Germany) and
used as reaction vessels. For the coupling of standard D- or L-
amino acid to the N-terminus of an amino acid or the amino
group of the Fmoc-Sieber-PS resin, DMF/NMP (8:2) was used
as solvent. Fmoc amino acids (5-fold excess) were preactivated
with HBTU/HOBt/DIPEA (5/5/10 equiv) for 5 min and
added to the resin. Double coupling at rt was performed for all
standard amino acids for 45 min. The coupling of the arginine
building block 32 and the dipeptides 17−19 (3-fold excess,
preactivated with HBTU/HOBt/DIPEA (3/3/6 equiv)) was
performed at 35 °C for 14 h (“single coupling”) using
anhydrous DMF as solvent. For the coupling of Fmoc amino
acids to a resin-bound aza-amino acid, triphosgene was used as
the coupling reagent. Triphosgene (1.75 equiv) was dissolved
in anhydrous THF and cooled to 0 °C. A solution of Fmoc
amino acid (5 equiv) and DIPEA (15 equiv) in anhydrous THF
was added dropwise causing the formation of a white
precipitate. After addition, stirring was continued for 5 min.
The suspension was centrifuged and the supernatant was added
to the resin. Coupling was performed at 35 °C for 12 h.
After coupling was completed, the resin was washed with
DMF/NMP and treated with 20% piperidine in DMF/NMP
(8:2) at rt (2×) for 10 min to remove the Fmoc group,
followed by thorough washing of the resin.
4.3.1. Benzyl (S)-2-Amino-3-[4-(tert-butoxy)phenyl]-
propanoate (15). Fmoc-Tyr(tBu)-OH (2 g, 4.35 mmol, 1
equiv), 4-DMAP (53.2 mg, 0.1 equiv), and benzyl alcohol (1
mL, 2.2 equiv) were dissolved in CH2Cl2 (25 mL) and a
solution of DCC (943 mg, 1.05 equiv) in CH2Cl2 (6 mL) was
added dropwise under ice-cooling. The mixture was stirred at rt
for 14 h. After completion of the reaction (monitored by thin-
layer chromatography (TLC) (light petroleum/EtOAc 2:1): Rf
= 0.76), the mixture was ﬁltered, and the ﬁltrate was washed
with 0.1 M HCl solution (30 mL) and brine (20 mL). The
volume of the organic layer was adjusted to 70 mL with
CH2Cl2, and diethylamine (12 mL) was added for removal of
the Fmoc group. After all of the starting material had been
consumed, the volatiles were removed on a rotary evaporator,
and the residue was taken up in light petroleum/EtOAc (1:1,
10 mL) and subjected to column chromatography (eluent: light
petroleum/EtOAc 1:1 → EtOAc/MeOH 4:1). The desired
compound was obtained as a yellowish highly viscous oil (1.05
g, 73.7%). 1H NMR (300 MHz, DMSO-d6): δ (ppm) 1.26 (s,
9H), 1.80 (br s, 2H), 2.71−2.89 (m, 2H), 3.60 (t, 2H, J 6.9
Hz), 5.05 (s, 2H), 6.84 (d, 2H, J 8.5 Hz), 7.06 (d, 2H, J 8.4
Hz), 7.25−7.39 (m, 5H). 13C NMR (100.6 MHz, DMSO-d6): δ
(ppm) 29.0 (3 carb), 56.4, 66.0, 78.0, 123.8 (2 carb), 128.40 (2
carb), 128.43, 128.8 (2 carb), 130.2 (2 carb), 132.9, 136.5,
153.9, 175.4. HRMS (ESI): m/z [M + H]+ calcd for
Figure 6. Competition binding performed with the radioligand 45 at
CHO-hY4R-Gqi5-mtAEQ cells. (A−C) Displacement of 45 (Kd = 0.67
nM, c = 0.6 nM). Data represent mean values ± SEM of at least three
independent experiments, each performed in triplicate.
Figure 7. Y1R antagonism of 31. Inhibition of pNPY (c = 10 nM, EC50
= 0.87 nM)-induced intracellular Ca2+ mobilization in HEL cells by 31
(Kb = 11.5 ± 1.1 nM), determined in a Fura-2 assay. Mean ± SEM
from three independent experiments.
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[C20H26NO3]
+: 328.1907, found: 328.1915. C20H25NO3
(327.42).
4.3.2. N2-(2-{[(9H-Fluoren-9-yl)methoxy]carbonyl}-1-iso-
butylhydrazine-1-carbonyl)-Nω-[(2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl]-L-arginine (17). Triphos-
gene (152 mg, 0.4 equiv) was dissolved in CH2Cl2 (5 mL).
A solution of 14 (145 mg, 0.442 mmol) and DIPEA (450 μL, 2
equiv) in CH2Cl2 (5 mL) was added dropwise under ice-
cooling. The mixture was allowed to warm to ambient
temperature under stirring for 30 min. A solution of 12 (200
mg, 1.1 equiv) in CH2Cl2 (2 mL) was added and stirring was
continued for 90 min. The mixture was diluted with EtOAc (60
mL) and washed with water. The volatiles were removed under
reduced pressure, the residue was taken up in EtOAc/hexane
(2:1, 10 mL) and subjected to column chromatography
(eluent: EtOAc/hexane (2:1)). The protected intermediate
was dissolved in MeOH (10 mL), and Pd/C-catalyst (50 mg)
was added. The mixture was stirred vigorously under hydrogen.
After completion of the hydrogenation, the solids were
removed by ﬁltration through celite, the volume was reduced
on a rotary evaporator. The desired compound was puriﬁed via
column chromatography (eluent: CH2Cl2/MeOH (10:1) →
CH2Cl2/MeOH (1:1) + 0.5% TFA). Removal of the volatiles
under reduced pressure and by lyophilization aﬀorded 14 as a
white lyophilisate (370 mg, 88.5%). TLC (CH2Cl2/MeOH
(10:0.6) + 1% AcOH): Rf = 0.28.
1H NMR (400 MHz,
methanol-d4): δ (ppm) 0.85 (s, 6H), 1.41 (s, 6H), 1.47−1.69
(m, 3H), 1.69−1.79 (m, 1H), 1.79−1.92 (m, 1H), 2.06 (s, 3H),
2.49 (s, 3H), 2.56 (s, 3H), 2.95 (s, 2H), 3.15 (s, 2H), 4.12−
4.30 (m, 2H), 4.52 (s, 2H), 7.28 (t, 2H, J 7.3 Hz), 7.37 (t, 2H, J
7.3 Hz), 7.54−7.70 (m, 2H), 7.77 (d, 2H, J 7.5 Hz). HRMS
(ESI): m/z [M + H]+ calcd for [C39H51N6O8S]
+: 763.3484,
found: 763.3494. C39H50N6O8S (762.92).
4.3.3. (S)-5-({[(9H-Fluoren-9-yl)methoxy]carbonyl}amino)-
2-[4-(tert-butoxy)benzyl]-12,12-dimethyl-4,10-dioxo-11-oxa-
3,5,9-triazatridecanoic Acid (18). Triphosgene (52.5 mg, 0.4
equiv) was dissolved in CH2Cl2 (2 mL). A solution of 15 (145
mg, 0.442 mmol) and DIPEA (150 μL, 2 equiv) in CH2Cl2 (2
mL) was added dropwise under ice-cooling. The mixture was
allowed to warm to ambient temperature under stirring for 30
min. A solution of 10 (200 mg, 1.1 equiv) in CH2Cl2 (2 mL)
was added, and stirring was continued for 90 min. The mixture
was diluted with EtOAc (40 mL) and washed with water. The
volatiles were removed under reduced pressure, the residue was
taken up in EtOAc/hexane (1:1, 10 mL) and subjected to
column chromatography (eluent: EtOAc/hexane (1:1), Rf =
0.57). The protected intermediate was dissolved in MeOH (10
mL), and Pd/C-catalyst (30 mg) was added. The mixture was
stirred vigorously under hydrogen. After completion of the
hydrogenation, the solids were removed by ﬁltration through
celite, the volume was reduced on a rotary evaporator. The
desired compound was puriﬁed via column chromatography
(eluent: CH2Cl2/MeOH (10:0.5) → CH2Cl2/MeOH (10:0.6)
+ 1% AcOH). Removal of the volatiles under reduced pressure
and by lyophilization aﬀorded 18 as a white lyophilisate (221
mg, 74.1%). TLC (CH2Cl2/MeOH (10:0.6) + 0.5% AcOH): Rf
= 0.35. 1H NMR (400 MHz, methanol-d4): δ (ppm) 1.20 (s,
9H), 1.42 (s, 9H), 1.51−1.66 (m, 2H), 2.81−3.20 (m, 5H),
3.69 (br s, 1H), 4.21 (s, 1H), 4.35−4.60 (m, 3H), 6.79 (s, 2H),
7.04 (s, 2H), 7.24−7.35 (m, 2H), 7.39 (t, 2H, J 7.2 Hz), 7.54−
7.73 (m, 2H), 7.80 (d, 2H, J 7.5 Hz). HRMS (ESI): m/z [M +
Table 2. NPY Y4R Agonist Potencies (EC50) and Intrinsic Activities (α) or Antagonism (IC50 Values)
aequorin assaya β-arrestin 1 assayb β-arrestin 2 assayb
compd EC50 or IC50 [nM] α EC50 or IC50 [nM] α EC50 or IC50 [nM] α
hPP 9.7c 1 3.54 ± 0.59 1 2.74 ± 0.23 1
(2R,7R)-1 6.9c 0.62 40.4 ± 11 0.54 31.8 ± 12 0.58
2 49c 0.73 n.d. n.d. n.d. n.d.
3 6390 ± 450 0.55 n.d. n.d. n.d. n.d.
4 226d n.a. 187 ± 72 n.a. 202 ± 78 n.a.
(2R,7R)-26e 388 ± 51 n.a. 5430 ± 350 n.a. 1320 ± 230 n.a.
27f 1430 ± 290 n.a. 1090 ± 350 n.a. 712 ± 87 n.a.
29 542 ± 110 0.07 875 ± 260 0.09 473 ±65 0.12
572 ± 59 n.a. n.d. n.d. n.d. n.d.
31 1340 ± 530 n.a. n.d. n.d. n.d. n.d.
33 2050 ± 84 0.44 2200 ± 130 0.56 1790 ± 1070 0.61
34 1460 ± 83 0.61 1070 ± 520 0.62 568 ± 120 0.60
35 187 ± 23 0.58 144 ± 28 0.48 124.1 ± 24 0.55
36 303 ± 68 0.78 187 ± 40 0.51 140 ± 45 0.54
37 9580 ± 2000 n.a. 6640 ± 780 n.a. 8050 ± 120 n.a.
38 18 800 ± 6500 n.a. 1310 ± 390 n.a. 1120 ± 250 n.a.
39 8340 ± 2900 n.a. n.d. n.d. n.d. n.d.
40 6000 ± 2600 n.a. n.d. n.d. n.d. n.d.
41 608 ± 140 0.61 2050 ± 780 0.46 710 ± 200 0.49
42 756 ± 230 0.63 2160 ± 600 0.45 624 ± 150 0.56
44 12 400 ± 5500 n.a. 5390 ± 1630 n.a. 3940 ± 660 n.a.
aAequorin calcium mobilization assay on CHO-hY4-Gqi5-mtAEQ cells.
26 Antagonism (IC50 values given in italics) was determined in the presence of
100 nM hPP (EC50 = 9.7 nM).
bβ-Arrestin 1,2 recruitment assay on HEK293T cells stably expressing the Y4R and ARRB1 or ARRB2. Antagonism
(IC50 values given in italics) was determined in the presence of 3 nM hPP (EC50 (ARRB1) = 3.54 nM; EC50 (ARRB2) = 2.74 nM).
cEC50 value
reported by Kuhn et al.11 dReported as Kb = 20 nM by Keller et al.
5 eY4R agonism on HEK293-hY4R-CRE Luc cells (luciferase reporter gene assay):
EC50 = 176 ± 50 nM, α = 0.81.
fY4R agonism on HEK293-hY4R-CRE Luc cells (luciferase reporter gene assay): EC50 = 220 ± 73 nM, α = 0.75.
Presented are mean values ± SEM from at least three independent experiments (performed in triplicate). n.a.: not applicable; n.d.: not determined.
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H]+ calcd for [C37H47N4O8]
+: 675.3388, found: 675.3403.
C37H46N4O8 (674.80).
4.3.4. {[1-(9H-Fluoren-9-yl)-12,12-dimethyl-3,10-dioxo-
2,11-dioxa-4,5,9-triazatridecan-5-yl]carbonyl}-L-leucine (19).
Triphosgene (52.5 mg, 0.4 equiv) was dissolved in CH2Cl2 (2
mL). A solution of 16 (97.7 mg, 0.442 mmol) and DIPEA (150
μL, 2 equiv) in CH2Cl2 (2 mL) was added dropwise under ice-
cooling. The mixture was allowed to warm to ambient
temperature under stirring for 30 min. A solution of 10 (200
mg, 1.1 equiv) in CH2Cl2 (2 mL) was added and stirring was
continued for 90 min. The mixture was diluted with EtOAc (40
mL) and washed with water. The volatiles were removed under
reduced pressure and the residue was taken up in EtOAc/
hexane (1:1, 10 mL) and subjected to column chromatography
(eluent: EtOAc/hexane (1:1), Rf = 0.71). The protected
intermediate was dissolved in MeOH (10 mL), and Pd/C-
catalyst (30 mg) was added. The mixture was stirred vigorously
under hydrogen. After completion of the hydrogenation, the
solids were removed by ﬁltration through celite, and the volume
was reduced on a rotary evaporator. The desired compound
was puriﬁed via column chromatography (eluent: CH2Cl2/
MeOH (10:0.4) → CH2Cl2/MeOH (10:0.6) + 0.1% TFA).
Figure 8. Y4R agonism of (2R,7R)-1, 33−36, 41, and 42 determined in a calcium (aequorin) assay, a β-arrestin recruitment assay, and a luciferase
reporter gene assay. (A, B) Induced intracellular Ca2+ mobilization in CHO-hY4R-mtAEQ-Gqi5 cells. (C, D) Induced β-arrestin 1 recruitment in
HEK293T-ARRB1-Y4R cells. (E, F) Induced β-arrestin 2 recruitment in HEK293T-ARRB2-Y4R cells. Data points shown for (A)−(F) are the mean
± SEM of at least three independent experiments performed in triplicate.
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Removal of the volatiles aﬀorded 19 as a sticky solid (132 mg,
52.5%). TLC (CH2Cl2/MeOH (10:0.6) + 0.5% AcOH): Rf =
0.55. 1H NMR (400 MHz, methanol-d4): δ (ppm) 0.90 (d, 6H,
J 4.4 Hz), 1.42 (s, 9H), 1.52−1.77 (m, 5H), 3.03 (s, 2H), 3.35−
3.95 (m, 2H), 4.23 (t, 1H, J 6.3 Hz), 4.29 (t, 1H, J 7.0 Hz), 4.52
(s, 2H), 7.31 (t, 2H, J 7.3 Hz), 7.39 (t, 2H, J 7.4 Hz), 7.59−7.71
(m, 2H), 7.79 (d, 2H, J 7.5 Hz). HRMS (ESI): m/z [M + H]+
calcd for [C30H41N4O7]
+: 569.2970, found: 569.2969.
C30H40N4O7 (568.67).
4.3.5. Tyr(tBu)-Arg(Pbf)-aza-Leu-Arg(Pbf)-Tyr(tBu)-amide
Hydrotriﬂuoroacetate (21). Compound 21 was synthesized
according to the general procedure (100 mg Fmoc-Sieber-PS
resin (loading: 0.61 mmol/g)). Puriﬁcation by preparative
HPLC (gradient: 0−18 min MeCN/0.1% aq TFA 42:58−
78:22, tR = 14.9 min) aﬀorded 21 as a white solid (39 mg,
42.6%). HRMS (ESI): m/z [M + 2H]2+ calcd for
[C69H105N13O13S2]
2+: 693.8693, found: 693.8708.
C69H103N13O13S2·C2HF3O2 (1386.06 + 114.02).
4.3.6. Tyr(tBu)-Arg(Pbf)-Leu-aza-Orn(Boc)-Tyr(tBu)-amide
Hydrotriﬂuoroacetate (22). Compound 22 was synthesized
according to the general procedure (100 mg Fmoc-Sieber-PS
resin (loading: 0.61 mmol/g)). Puriﬁcation by preparative
HPLC (gradient: 0−20 min MeCN/0.1% aq TFA 42:58−
78:22, tR = 14.2 min) gave 22 as a white solid (42 mg, 52.7%).
HRMS (ESI): m/z [M + 2H]2+ calcd for [C60H95N11O12S]
2+:
Figure 9. Y4R antagonism of (2R,7R)-26 and 27 determined in a
calcium (aequorin) assay, a β-arrestin recruitment assay, and a
luciferase reporter gene assay. (A) Inhibition of hPP (EC50 = 9.7 nM, c
= 100 nM)-induced Ca2+ mobilization in CHO-hY4R-mtAEQ-Gqi5
cells. (B) Inhibition of hPP (EC50 (Arr1) = 3.54 nM, EC50 (Arr2) =
2.74 nM, c = 3 nM)-induced β-arrestin 1,2 recruitment in HEK293T-
ARRB1-Y4R cells (β-arrestin 1, solid lines) and HEK293T-ARRB2-
Y4R cells (β-arrestin 2, dashed lines). (C) Inhibition of forskolin-
stimulated (2 μM) luciferase activity (corresponding to 100%) in hY4R
expressing HEK293 cells with the maximum inhibitory eﬀect of the
endogenous ligand hPP, which was set to 0% luciferase activity and
corresponds to full agonism (α = 1.0). Data points shown for (A)−
(C) are the mean ± SEM of at least three independent experiments
performed in triplicate.
Figure 10. Y4R functional activity of 38 and 44 determined in a
calcium (aequorin) assay and a β-arrestin recruitment assay. (A)
Inhibition of hPP (EC50 = 9.7 nM, c = 100 nM)-induced intracellular
Ca2+ mobilization in CHO-hY4R-mtAEQ-Gqi5 cells. (B) Inhibition of
hPP (EC50 (Arr1) = 3.54 nM, EC50 (Arr2) = 2.74 nM, c = 3 nM)-
induced β-arrestin 1,2 recruitment in HEK293T-ARRB1-Y4R cells (β-
arrestin 1, solid lines) and HEK293T-ARRB2-Y4R cells (β-arrestin 2,
dashed lines). Data points shown for (A) and (B) are the mean ±
SEM of at least three independent experiments performed in triplicate.
Note: Inhibition of hPP-induced response appears incomplete,
however, concentrations of antagonists higher than those given in
the curves could not be applied due to a shortage of the test
compounds. There was no intrinsic activity of both compounds in the
respective assays when performed in the agonist mode (SI Figures 3, 5,
and 7).
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596.8436, found: 596.8445. C60H93N11O12S·C2HF3O2 (1192.53
+ 114.02).
4.3.7. Tyr(tBu)-aza-Orn(Boc)-Leu-Arg(Pbf)-Tyr(tBu)-amide
Hydrotriﬂuoroacetate (23). Compound 23 was synthesized
according to the general procedure (100 mg Fmoc-Sieber-PS
resin (loading: 0.61 mmol/g)). Puriﬁcation by preparative
HPLC (gradient: 0−20 min MeCN/0.1% aq TFA 42:58−
78:22, tR = 14.6 min) aﬀorded 23 as a white solid (36 mg,
45.2%). HRMS (ESI): m/z [M + 2H]2+ calcd for
[C60H95N11O12S]
2+ : 596 .8436 , found: 596 .8446 .
C60H93N11O12S·C2HF3O2 (1192.53 + 114.02).
4.3.8. (2R,7R)-Diaminooctanedioyl-bis(Tyr-Arg-aza-Leu-
Arg-Tyr-amide) Hexakis(hydrotriﬂuoroacetate) ((2R,7R)-26).
Compound 24 (2.08 mg, 5.1 μmol), HBTU (4.1 mg, 2.1
equiv), and HOBt (1.57 mg, 2 equiv) were dissolved in
anhydrous DMF (400 μL). DIPEA (10 μL, 5 equiv) was added.
Stirring was continued at rt for 5 min, followed by addition of a
solution of 21 (19.3 mg, 12.8 μmol) in DMF. The mixture was
stirred at 35 °C for 16 h. Water (10 mL) was added and the
protected intermediate was extracted with CH2Cl2 (2 × 10
mL). The combined organic phases were concentrated, and the
residue was dried in vacuo. TFA/water (95:5, 2 mL) was
added, and the mixture was stirred at rt for 2.5 h. Water (100
mL) was added followed by lyophilization. The product was
puriﬁed by preparative HPLC (gradient: 0−20 min: MeCN/
0.1% aq TFA 3:97−42:58, tR = 15.6 min). Freeze-drying of the
eluate gave (2R,7R)-26 as a white ﬂuﬀy solid (3.45 mg, 28.3%).
HRMS (ESI): m/z [M + 4H]4+ calcd for [C78H126N28O16]
4+:
427.7471, found: 427.7485. RP-HPLC (220 nm): 99% (tR =
17.72 min, k = 5.2). C78H122N28O16·C12H6F18O12 (1708.01 +
684.12).
4.3.9. Octanedioyl-bis(Tyr-Arg-aza-Leu-Arg-Tyr-amide)
Tetrakis(hydrotriﬂuoroacetate) (27). Compound 21 (28.8
mg, 19.2 μmol) was dissolved in anhydrous DMF/DIPEA
(99:1 v/v) (600 μL). Compound 25 (2.83 mg, 7.7 μmol) was
added, and the mixture was stirred at 35 °C for 16 h. Water (10
mL) was added, and the protected intermediate was extracted
with CH2Cl2 (2 × 10 mL). The combined extracts were
evaporated, and the residue was dried in vacuo. TFA/water
(95:5 v/v) (2 mL) was added, and the mixture was stirred at rt
for 2.5 h. Water (100 mL) was added followed by
lyophilization. The product was puriﬁed by preparative
HPLC (gradient: 0−20 min: MeCN/0.1% aq TFA 3:97−
42:58, tR = 16.5 min). Lyophilization of the eluate aﬀorded 27
as a white ﬂuﬀy solid (6.3 mg, 38.3%). HRMS (ESI): m/z [M +
4H]4+ calcd for C78H124N26O16: 420.2417, found: 420.2433.
RP-HPLC (220 nm): 95% (tR = 19.13 min, k = 5.7).
C78H120N26O16·C8H4F12O8 (1677.98 + 456.08).
4.3.10. Octanedioyl-bis(Tyr-Arg-Leu-aza-Orn-Tyr-amide)
Tetrakis(hydrotriﬂuoroacetate) (28). Compound 22 (16.7
mg, 12.8 μmol) was dissolved in anhydrous DMF/DIPEA
(99:1 v/v) (600 μL). Compound 25 (1.9 mg, 5.1 μmol) was
added, and the mixture was stirred at 35 °C for 16 h. After
addition of water (10 mL), the protected intermediate was
extracted with CH2Cl2 (2 × 10 mL). The combined extracts
were evaporated, and the residue was dried in vacuo. TFA/
water (95:5 v/v) (2 mL) was added, and the mixture was
stirred at rt for 2.5 h. Water (100 mL) was added, followed by
lyophilization. The product was puriﬁed by preparative HPLC
(gradient: 0−20 min: MeCN/0.1% aq TFA 3:97−42:58, tR =
16.1 min). Lyophilization of the eluate aﬀorded 28 as a white
ﬂuﬀy solid (4.2 mg, 40.2%). HRMS (ESI): m/z [M + 4H]4+
calcd for C76H120N22O16: 399.2308, found: 399.2327. RP-
HPLC (220 nm): 99% (tR = 19.55 min, k = 5.8).
C76H116N22O16·C8H4F12O8 (1593.90 + 456.08).
4.3.11. Octanedioyl-bis(Tyr-Arg-Leu-aza-Arg-Tyr-amide)
Tetrakis(hydrotriﬂuoroacetate) (29). Compound 28 (3.7 mg,
2.05 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/
v) (300 μL). A solution of N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (1 mg/10 μL, 16 μL, 2.5 equiv) was added,
and the mixture was stirred at rt for 4 h. After addition of water
(5 mL), the protected intermediate was puriﬁed by preparative
HPLC (gradient: 0−25 min: MeCN/0.1% aq TFA 3:97−52:48,
tR = 26.4 min). The eluates were subjected to lyophilization,
and the residue was taken up in TFA/CH2Cl2/H2O (5:5:0.5, 3
mL). The resulting mixture was stirred for 3 h. The volatiles
were removed on a rotary evaporator and by lyophilization. 29
was obtained as a white ﬂuﬀy solid (1.62 mg, 37.0%). HRMS
(ESI): m/z [M + 4H]4+ calcd for C78H124N26O16: 420.2417,
found: 420.2434. RP-HPLC (220 nm): >99% (tR = 20.15 min,
k = 6.0). C78H120N26O16·C8H4F12O8 (1677.98 + 456.08).
4.3.12. Octanedioyl-bis(Tyr-aza-Orn-Leu-Arg-Tyr-amide)
Tetrakis(hydrotriﬂuoroacetate) (30). Compound 23 (16.7
mg, 12.8 μmol) was dissolved in anhydrous DMF/DIPEA
(99:1 v/v) (600 μL). Compound 25 (1.88 mg, 5.1 μmol) was
added, and the mixture was stirred at 35 °C for 16 h. After
addition of water (10 mL), the protected intermediate was
extracted with CH2Cl2 (2 × 10 mL). The combined extracts
were evaporated, and the residue was dried in vacuo. TFA/
water (95:5 v/v) (2 mL) was added, and the mixture was
stirred at rt for 2.5 h. Water (100 mL) was added followed by
lyophilization. The product was puriﬁed by preparative HPLC
(gradient: 0−20 min: MeCN/0.1% aq TFA 6:94−37:63, tR =
17.4 min). Lyophilization of the eluate aﬀorded 30 as a white
ﬂuﬀy solid (3.9 mg, 37.3%). HRMS (ESI): m/z [M + 4H]4+
calcd for C76H120N22O16: 399.2308, found: 399.2317. RP-
HPLC (220 nm): 98% (tR = 20.13 min, k = 6.0).
C76H116N22O16·C8H4F12O8 (1593.90 + 456.08).
4.3.13. Octanedioyl-bis(Tyr-aza-Arg-Leu-Arg-Tyr-amide)
Tetrakis(hydrotriﬂuoroacetate) (31). Compound 30 (3.0 mg,
1.66 μmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/
v) (300 μL). A solution of N,N′-di-Boc-1H-pyrazole-1-
carboxamidine (1 mg/10 μL, 13 μL, 2.5 equiv) was added,
and the mixture was stirred at rt for 4 h. After addition of water
(5 mL), the protected intermediate was puriﬁed by preparative
HPLC (gradient: 0−25 min: MeCN/0.1% aq TFA 3:97−52:48,
tR = 26.1 min). The solvents were removed by lyophilization,
the residue was taken up in TFA/CH2Cl2/H2O (5:5:0.5, 3
mL), and the resulting mixture was stirred for 3 h. The volatiles
were removed on a rotary evaporator and by lyophilization. The
title compound was obtained as a white ﬂuﬀy solid (1.50 mg,
42.3%). HRMS (ESI): m/z [M + 4H]4+ calcd for
C78H124N26O16: 420.2417, found: 420.2437. RP-HPLC (220
nm): 96% (tR = 20.86 min, k = 6.3). C78H120N26O16·C8H4F12O8
(1677.98 + 456.08).
4.3.14. Octanoyl-Tyr-Arg-Leu-Arg-Tyr-amide Bis-
(hydrotriﬂuoroacetate) (33). The pentapeptide 33 was
synthesized according to the general procedure (82 mg
Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Puriﬁcation
by preparative HPLC (gradient: 0−18 min MeCN/0.1% aq
TFA 22:78−51:49, tR = 13.2 min) aﬀorded 33 as a white solid
(33.4 mg, 59.5%). HRMS (ESI): m/z [M + 2H]2+ calcd for
[C44H72N12O8]
2+: 448.2793, found: 448.2800. RP-HPLC (220
nm): 99% (tR = 28.04 min, k = 8.8). C44H70N12O8·C4H2F6O4
(895.13 + 228.04).
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4.3.15. Ac-Tyr-Nω-[(4-aminobutyl)aminocarbonyl]Arg-Leu-
Arg-Tyr-amide Tris(hydrotriﬂuoroacetate) (34). The penta-
peptide 34 was synthesized according to the general procedure
(18.8 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)).
Puriﬁcation by preparative HPLC (gradient: 0−18 min MeCN/
0.1% aq TFA 3:97−42:58, tR = 14.4 min) gave 34 as a white
solid (7.7 mg, 53.0%). HRMS (ESI): m/z [M + 3H]3+ calcd for
[C43H71N14O9]
3+: 309.1837, found: 309.1850. RP-HPLC (220
nm): 97% (tR = 16.96 min, k = 4.9). C43H68N14O9·C6H3F9O6
(925.12 + 342.06).
4.3.16. Ac-Arg-Tyr-Nω-[(4-aminobutyl)aminocarbonyl]Arg-
Leu-Arg-Tyr-amide Tetrakis(hydrotriﬂuoroacetate) (35). The
hexapeptide 35 was synthesized according to the general
procedure (18.8 mg Fmoc-Sieber-PS resin (loading: 0.61
mmol/g)). Puriﬁcation by preparative HPLC (gradient: 0−18
min MeCN/0.1% aq TFA 3:97−42:58, tR = 13.6 min) yielded
35 as a white solid (9.3 mg, 52.7%). HRMS (ESI): m/z [M +
4H]4+ calcd for [C49H84N18O10]
4+: 271.1649, found: 217.1657.
RP-HPLC (220 nm): 97% (tR = 15.22 min, k = 4.3).
C49H80N18O10·C8H4F12O8 (1081.31 + 456.08).
4.3.17. Ac-Arg-Tyr-Arg-Leu-Arg-Tyr-amide Tris-
(hydrotriﬂuoroacetate) (36). The hexapeptide 36 was
synthesized according to the general procedure (35 mg
Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Puriﬁcation
by preparative HPLC (gradient: 0−18 min MeCN/0.1% aq
TFA 3:97−42:58, tR = 13.7 min) aﬀorded 36 as a white solid
(18.3 mg, 65.5%). HRMS (ESI): m/z [M + 3H]3+ calcd for
[C44H70N16O9]
3+: 323.1910, found: 323.1927. RP-HPLC (220
nm): 99% (tR = 15.98 min, k = 4.6). C44H70N16O9·C6H3F9O6
(967.15 + 342.06).
4.3.18. Ac-Arg-Tyr-Arg-Leu-Nω- [ (4-aminobutyl)-
a m i n o c a r b o n y l ] A r g - T y r - a m i d e T e t r a k i s -
(hydrotriﬂuoroacetate) (37). The hexapeptide 37 was
synthesized according to the general procedure (35 mg
Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Puriﬁcation
by preparative HPLC (gradient: 0−18 min MeCN/0.1% aq
TFA 3:97−42:58, tR = 13.6 min) gave 37 as a white solid (7.2
mg, 21.9%). HRMS (ESI): m/z [M + 3H]3+ calcd for
[C49H83N18O10]
3+: 361.2174, found: 361.2187. RP-HPLC
(220 nm): 99% (tR = 15.17 min, k = 4.3). C49H80N18O10·
C8H4F12O8 (1081.31 + 456.08).
4.3.19. Ac-Arg-Tyr-Nω-[(4-aminobutyl)aminocarbonyl]Arg-
Leu-Arg-D-Tyr-amide Tetrakis(hydrotriﬂuoroacetate) (38).
The hexapeptide 38 was synthesized according to the general
procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/
g)). Puriﬁcation by preparative HPLC (gradient: 0−18 min
MeCN/0.1% aq TFA 3:97−42:58, tR = 13.6 min) aﬀorded 38
as a white solid (5.7 mg, 17.4%). HRMS (ESI): m/z [M +
4H]4+ calcd for [C49H84N18O10]
4+: 271.1649, found: 217.1666.
RP-HPLC (220 nm): 98% (tR = 15.25 min, k = 4.3).
C49H80N18O10·C8H4F12O8 (1081.31 + 456.08).
4.3.20. Ac-Arg-Tyr-Nω-[(4-aminobutyl)aminocarbonyl]Arg-
Leu-D-Arg-Tyr-amide Tetrakis(hydrotriﬂuoroacetate) (39).
The hexapeptide 39 was synthesized according to the general
procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/
g)). Puriﬁcation by preparative HPLC (gradient: 0−18 min
MeCN/0.1% aq TFA 3:97−42:58, tR = 13.3 min) yielded 39 as
a white solid (6.0 mg, 18.3%). HRMS (ESI): m/z [M + 3H]3+
calcd for [C49H83N18O10]
3+: 361.2174, found: 361.2190. RP-
HPLC (220 nm): 95% (tR = 14.77 min, k = 4.1).
C49H80N18O10·C8H4F12O8 (1081.31 + 456.08).
4.3.21. Ac-Arg-Tyr-Nω-[(4-aminobutyl)aminocarbonyl]Arg-
D-Leu-Arg-Tyr-amide Tetrakis(hydrotriﬂuoroacetate) (40).
The hexapeptide 40 was synthesized according to the general
procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/
g)). Puriﬁcation by preparative HPLC (gradient: 0−18 min
MeCN/0.1% aq TFA 3:97−42:58, tR = 13.4 min) aﬀorded 40
as a white solid (6.6 mg, 20.1%). HRMS (ESI): m/z [M +
3H]3+ calcd for [C49H83N18O10]
3+: 361.2174, found: 361.2189.
RP-HPLC (220 nm): 96% (tR = 14.33 min, k = 4.0).
C49H80N18O10·C8H4F12O8 (1081.31 + 456.08).
4 . 3 . 22 . A c -A rg -D - T y r - {Nω - [N - ( 4 -am inobu t y l ) -
aminocarbonyl] }Arg-Leu-Arg-Tyr-amide Tetrakis-
(hydrotriﬂuoroacetate) (41). The hexapeptide 41 was
synthesized according to the general procedure (35 mg
Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Puriﬁcation
by preparative HPLC (gradient: 0−18 min MeCN/0.1% aq
TFA 3:97−42:58, tR = 13.5 min) gave 41 as a white solid (6.7
mg, 20.5%). HRMS (ESI): m/z [M + 3H]3+ calcd for
[C49H83N18O10]
3+: 361.2174, found: 361.2190. RP-HPLC
(220 nm): 95% (tR = 15.1 min, k = 4.3). C49H80N18O10·
C8H4F12O8 (1081.31 + 456.08).
4 . 3 . 23 . A c - D -A rg - Ty r - {Nω - [N - ( 4 -am inobu t y l ) -
aminocarbonyl] }Arg-Leu-Arg-Tyr-amide Tetrakis-
(hydrotriﬂuoroacetate) (42). The hexapeptide 42 was
synthesized according to the general procedure (35 mg
Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Puriﬁcation
by preparative HPLC (gradient: 0−18 min MeCN/0.1% aq
TFA 3:97−42:58, tR = 13.5 min) aﬀorded 42 as a white solid
(7.0 mg, 21.4%). HRMS (ESI): m/z [M + 3H]3+ calcd for
[C49H83N18O10]
3+: 361.2174, found: 361.2190. RP-HPLC (220
nm): 99% (tR = 14.94 min, k = 4.2). C49H80N18O10·C8H4F12O8
(1081.31 + 456.08).
4 . 3 . 2 4 . A c - A r g - T y r - { N ω - [ N - ( 4 - am i n o bu t y l ) -
am inoca rbony l ] } A rg - L eu -A rg - Ty r -OH Te t rak i s -
(hydrotriﬂuoroacetate) (43). The hexapeptide 43 was
synthesized according to the general procedure (44.1 mg, H-
L-Tyr(tBu)-2CT resin (loading: 0.68 mmol/g)). Puriﬁcation by
preparative HPLC (gradient: 0−18 min MeCN/0.1% aq TFA
13:87−42:58, tR = 10.7 min) yielded 43 as a white solid (15.2
mg, 32.9%). HRMS (ESI): m/z [M + 4H]4+ calcd for
[C49H83N17O11]
4+: 271.4109, found: 271.4124. RP-HPLC
(220 nm): 95% (tR = 16.28 min, k = 4.7). C49H79N17O11·
C8H4F12O8 (1082.28 + 456.08).
4.3.25. (S)-2-Acetamido-N-((S)-1-{[(12S,15S,18S,21S)-2-
amino-15-(3-guanidinopropyl)-12-(4-hydroxybenzyl)-18-iso-
butyl-4,11,14,17,20-pentaoxo-1,3,5,10,13,16,19-heptaazacy-
clotetracos-2-en-21-yl]amino}-3-(4-hydroxyphenyl)-1-oxo-
p r o p an - 2 - y l ) - 5 - g u an i d i n o p e n t a n am i d e T r i s -
(hydrotriﬂuoroacetate) (44). Compound 43 (9.0 mg, 5.85
μmol), HOBt (1.79 mg, 2 equiv), and DIPEA (0.9 μL, 8 equiv)
were dissolved in anhydrous DMF (5850 μL) to give a 1 mM
solution. A solution of PyBOP (3.65 mg, 1.2 equiv) was added
dropwise. After stirring at rt for 24 h, 0.1% aq TFA (20 mL)
was added, and puriﬁcation by preparative HPLC (gradient: 0−
18 min MeCN/0.1% aq TFA 3:97−42:58, tR = 15.9 min)
aﬀorded 44 as a white solid (3.9 mg, 47.4%). HRMS (ESI): m/
z [M + 3H]3+ calcd for [C49H80N17O10]
3+: 355.5419, found:
355.5434. RP-HPLC (220 nm): 95% (tR = 18.4 min, k = 5.4).
C49H77N17O10·C6H3F9O6 (1064.27 + 342.06).
4.4. Cells. HEC-1B (HTB-113) human endometrial cancer
cells were from the American Type Culture Collection
(Rockville, MD). MCF-7-Y1 cells were previously established
in our laboratory.23 HEL cells were kindly provided by Dr. M.
C. Michel (Universitaẗsklinikum Essen, Germany), and CHO-
K1 (ACC-110) cells and HEK293T (ACC 635) cells were from
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Deutsche Sammlung für Mikroorganismen und Zellkulturen
(DSMZ, Braunschweig, Germany).
Routinely performed examinations for mycoplasma contam-
ination using the Venor GeM Mycoplasma Detection Kit
(Minerva Biolabs, Berlin, Germany) were negative for all cell
types.
4.4.1. HEK293T-ARRB1-hY4R and HEK293T-ARRB2-hY4R
Cells. The β-arrestin recruitment was quantiﬁed by a luciferase
complementation assay based on the emerald luciferase (ELuc)
from the brazilian click-beetle Pyrearinus termitilluminans. The
fusion construct of the human hY4R (the hY4R cDNA was from
cDNA Resource Center, Bloomsburg, PA) and the C-terminal
luciferase fragment (hY4R-ELucC) was generated using the
previously described construct SSTR2-ELucC31,32 by replacing
the cDNA of SSTR2 with the cDNA of the hY4R. HEK293T
cells were stably transfected with the pcDNA3.1/myc-HIS (B)
vector encoding the β-arrestin isoform 1 or 2, N-terminally
fused with the N-terminus of the luciferase (ELucN-ARRB1 or
ELucN-ARRB2, respectively)31 and the pcDNA4/V5-HIS (B)
vector encoding hY4R-ELucC using G418 (600 μg/mL) and
zeocin (40 μg/mL) as selection antibiotics, as previously
described for the H1R.
33 To determine the hY4R-ELucC
expression, saturation binding studies were performed with
both HEK293T-ARRB1-hY4R cells and HEK293T-ARRB2-
hY4R cells using the radioligand 45 (cf. SI Figures S6 and S7).
4.5. Cell Culture. Cells were maintained in 25 or 75 cm2
ﬂasks (Sarstedt, Nümbrecht, Germany) in a humidiﬁed
atmosphere (95% air, 5% CO2) at 37 °C. MCF-7-Y1 cells,
22
HEL cells,34 CHO-hY2-Gqi5-mtAEQ cells,
26 CHO-hY4-Gqi5-
mtAEQ cells,26 and HEK293T-hY4R-CRE Luc cells
11 were
cultured as described previously. HEK293T-ARRB1-hY4R and
HEK293T-ARRB2-hY4R cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium containing 10% FCS, 600 μg/mL
G418, and 40 μg/mL zeocin.
4.6. Radioligand Binding Assays. Radioligand binding
assays at all NPY receptor subtypes were performed at 22 ± 1
°C according to the experimental protocols described in detail
previously.11 Radioactivity (dpm) was measured with a
MicroBeta2 plate counter (PerkinElmer, Rodgau, Germany).
Cells, buﬀers, radioligands, and the respective Kd values and
concentrations, as well as the assay conditions are summarized
in Table 3.
4.7. Fura-2 Calcium Assay. The assay was performed with
HEL cells as previously described.34,35
4.8. Aequorin Calcium Assay. The assay was performed
on CHO-hY4-Gqi5-mtAEQ cells as previously described
26 using
a GENios Pro plate reader (Tecan, Salzburg, Austria). Areas
under the curve were calculated using SigmaPlot 12.5 software
(Systat Software Inc., Chicago, IL).
4.9. Luciferase Assay. The Luciferase assay was performed
on HEK293-hY4-CRE Luc cells as previously described.
11
4.10. β-Arrestin Recruitment Assay. The recruitment of
β-arrestin was measured via the split-luciferase complementa-
tion technique.32 Agonist potencies were determined on
HEK293T-ARRB1-Y4R and HEK293T-ARRB2-Y4R cells
using the GENios Pro microplate reader (Tecan, Salzburg,
Austria) as previously described for HEK293T-ARRB1-H1R
and HEK293T-ARRB2-H2R, respectively.
33 For the determi-
nation of antagonism, the cells were preincubated in the
presence of the antagonist for 15 min. Ten microliters of an
hPP solution (30 nM, ﬁnal concentration 3 nM) was added and
incubation was continued at 25 °C for 60 min. The plates were
further processed as in the case of the agonist mode.
4.11. Data Analysis. Concentration response curves from
functional assays and displacement curves from radioligand
competition binding were analyzed by four-parameter
sigmoidal ﬁts (GraphPad Prism 5.0, San Diego, CA). Agonist
potencies are given as EC50 values, intrinsic activities are
expressed as α values with respect to the eﬀect of 1 μM hPP
(maximal response α = 1.0). Antagonistic activities were
determined in the presence of 3 nM hPP (β-arrestin 1/2 assay,
EC50 = 3.54 nM (ARRB1), EC50 = 2.74 nM (ARRB2)), 100
nM hPP (aequorin assay, EC50 = 9.7 nM) or 10 nM pNPY
(Fura-2 Ca2+ assay, EC50 = 0.87 nM (Y1R)). Ki and Kb (Fura-2
Ca2+ (Y1R)) values were calculated from IC50 values using the
Cheng−Prusoﬀ equation.36
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Table 3. Conditions of the Radioligand Competitions Binding Assays at the NPY Receptor Subtypes
Y1R Y2R Y4R Y5R
receptor source MCF-7-Y1 cells
23 CHO-hY2R-Gqi5-mtAEQ
cells25
CHO-hY4R-Gqi5-mtAEQ
cells26
HEC-1B-hY5 cells
27
buﬀer N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid
(HEPES) buﬀer containing 150 mM NaCla
sodium-free HEPES
buﬀerb
sodium-free HEPES
buﬀerb
HEPES buﬀer containing
150 mM NaCla
radioligand compd 46 [3H]propionyl-pNPY compd 4511 [3H]propionyl-pNPY
Kd 6.2 nM 1.4 nM 0.67 nM 4.8 nM
concentration 4 nM 1.0 nM 0.6 nM 4 nM
incubation
period
90 min 90 min 90 min 120 min
separation suction suction ﬁltration suction
scintillation
cocktail
Optiphase Supermix Optiphase Supermix Rotiscint eco plus Optiphase Supermix
aIsotonic HEPES buﬀer pH 7.4 (150 mM NaCl, 10 mM HEPES, 25 mM NaHCO3, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 5 mM KCl).
bHypotonic, sodium-free HEPES buﬀer pH 7.4 (25 mM HEPES, 2.5 mM CaCl2, 1 mM MgCl2). Binding buﬀers were supplemented with BSA (1%)
and bacitracin (0.1 mg/mL).
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